Stoke Therapeutics Q1 Update: OLE Data Positive, but Risks Remain

What happened

Stoke Therapeutics reported that its lead therapy zorevunersen continues to show durable seizure reductions and improvements in cognition and behavior in four-year open-label extension data. The company also stated it remains on track to complete enrollment in the pivotal Phase 3 EMPEROR study by June 2026. However, the stock trades near $33 with a market cap of $1.9B, pricing in a clean execution path that may be optimistic given ongoing risks. Key concerns include significant ATM equity dilution ($80.7M raised in Q1), a high incidence of CSF protein elevations in ~94% of patients, and Europe enrollment completion still expected in 3Q26, leaving timeline uncertainty. The news does not alter the fundamental setup; the stock remains a WAIT with an attractive entry near $28.

Implication

The positive OLE data supports the clinical narrative but does not resolve key risks of dilution, safety monitoring, and timeline execution. Investors should use strength to reduce exposure and wait for either a pullback to $28 or explicit de-risking events (e.g., Europe enrollment completion, reduced ATM pace).

Thesis delta

The Q1 update confirms enrollment is on track and OLE data remains supportive, but these were already priced in. No material shift in risk/reward; the thesis remains anchored to observable execution metrics and financing discipline. The bear case timeline slip and dilution risks are still present.